Interferon-β–Induced Pulmonary Arterial Hypertension: Approach to Diagnosis and Clinical Monitoring

Farhan Raza, Callyn Kozitza, Amy Chybowski, Kara N. Goss, Theodore Berei, James Runo, Marlowe Eldridge, Naomi Chesler

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


A 48-year-old woman who had been receiving long-term interferon-β for 8 years for multiple sclerosis developed drug-induced World Health Organization group I pulmonary arterial hypertension. Triple therapy for pulmonary arterial hypertension and suspension of interferon-β led to improvement from a high-risk to low-risk state and improvement in exercise hemodynamics, including vascular distensibility, and right ventricle–pulmonary artery coupling. (Level of Difficulty: Advanced.)

Original languageEnglish (US)
Pages (from-to)1038-1043
Number of pages6
JournalJACC: Case Reports
Issue number7
StatePublished - Jul 7 2021
Externally publishedYes


  • exercise
  • pulmonary hypertension
  • right ventricle

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Interferon-β–Induced Pulmonary Arterial Hypertension: Approach to Diagnosis and Clinical Monitoring'. Together they form a unique fingerprint.

Cite this